Gómez-Gómez GJ, Masedo &, Yela C, Martínez-Montiel MDP, Casís B. Current stage in inflammatory bowel disease: What is next? World J Gastroenterol 2015; 21(40): 11282-11303 [PMID: 26525013 DOI: 10.3748/wjg.v21.i40.11282]
Corresponding Author of This Article
Dr. Maria del Pilar Martínez-Montiel, PhD, Unidad de Enfermedad Inflamatoria Intestinal, Hospital 12 de Octubre, Av\ Córdoba s/n, 28045 Madrid, Spain. pilarmarmon123@telefonica.net
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Topic Highlight
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Oct 28, 2015; 21(40): 11282-11303 Published online Oct 28, 2015. doi: 10.3748/wjg.v21.i40.11282
Current stage in inflammatory bowel disease: What is next?
Gonzalo Jesús Gómez-Gómez, Ángeles Masedo, Carmen Yela, Maria del Pilar Martínez-Montiel, Begoña Casís
Gonzalo Jesús Gómez-Gómez, Ángeles Masedo, Carmen Yela, Maria del Pilar Martínez-Montiel, Begoña Casís, Unidad de Enfermedad Inflamatoria Intestinal, Hospital 12 de Octubre, 28045 Madrid, Spain
Author contributions: Gómez-Gómez GJ, Masedo Á, Yela C, Martínez-Montiel MP and Casís B analyzed the literature and wrote the manuscript.
Conflict-of-interest statement: The authors have no conflict of interest to report.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Maria del Pilar Martínez-Montiel, PhD, Unidad de Enfermedad Inflamatoria Intestinal, Hospital 12 de Octubre, Av\ Córdoba s/n, 28045 Madrid, Spain. pilarmarmon123@telefonica.net
Telephone: +34-91-7792667
Received: June 1, 2015 Peer-review started: June 2, 2015 First decision: June 23, 2015 Revised: July 12, 2015 Accepted: September 2, 2015 Article in press: September 2, 2015 Published online: October 28, 2015
Abstract
In recent years, the incidence of inflammatory bowel disease (IBD) has been on the rise, extending to countries where it was infrequent in the past. As a result, the gap between high and low incidence countries is decreasing. The disease, therefore, has an important economic impact on the healthcare system. Advances in recent years in pharmacogenetics and clinical pharmacology have allowed for the development of treatment strategies adjusted to the patient profile. Concurrently, new drugs aimed at inflammatory targets have been developed that may expand future treatment options. This review examines advances in the optimization of existing drug treatments and the development of novel treatment options for IBD.
Core tip: The incidence and prevalence of inflammatory bowel disease (IBD) has been increasing worldwide. In recent years, the treatment objectives, the monitoring of IBD, and the drug treatments for controlling the disorder have been evolving. This review summarizes recent developments in pharmacogenetics, clinical pharmacology, and the use of new drug molecules that may expand IBD treatment options in the future.
